乳头状甲状腺癌患者血清和甲状腺组织中白细胞介素6水平的检测及其意义

doi:10.13481/j.1671-587x.20190322

吉林大学学报(医学版) ›› 2019, Vol. 45 ›› Issue (03): 601-605.doi: 10.13481/j.1671-587x.20190322

• 临床研究 • 上一篇

乳头状甲状腺癌患者血清和甲状腺组织中白细胞介素6水平的检测及其意义

黑利娟^1,2, 王娟红^3,4, 魏威⁴, 方航荣⁴, 段瑛⁴, 马士芬^1,2, 徐俊荣¹

1. 西安交通大学医学院附属西安市中心医院消化科, 陕西西安 710000;
2. 延安大学医学院, 陕西延安 716000;
3. 西安交通大学医学院附属西安市中心医院病理科, 陕西西安 710000;
4. 陕西省西安市第三医院病理科, 陕西西安 710003

收稿日期:2018-08-28 发布日期:2019-06-05
通讯作者: 王娟红,主任医师(Tel:029-61816314,E-mail:657237987@qq.com) E-mail:657237987@qq.com
作者简介:黑利娟(1990-),女,陕西省榆林市人,住院医师,在读医学硕士,主要从事功能性胃肠病方面的研究。
基金资助:
国家自然科学基金资助课题（81372857）；陕西省科技厅科技研究发展计划项目资助课题（2008K09-09）；陕西省西安市科技局科技计划项目资助课题[SF09027（9）]

Detection of interleukin-6 levels in serum and thyroid tissue of patients with papillary thyroid carcinoma and their significances

HEI Lijuan^1,2, WANG Juanhong^3,4, WEI Wei⁴, FANG Hangrong⁴, DUAN Ying⁴, MA Shifen^1,2, XU Junrong¹

1. Department of Gastroenterology, Xi'an Central Hospital, School of Medical Sciences, Xi'an Jiaotong University, Xi'an 710003, China;
2. College of Medical Sciences, Yan'an University, Yan'an 716000, China;
3. Department of Pathology, Xi'an Central Hospital, School of Medical Sciences, Xi'an Jiaotong University, Xi'an 710003, China;
4. Department of Pathology, Xi'an Third Hospital, Shannxi Province, Xi'an 710000, China

Received:2018-08-28 Published:2019-06-05

摘要/Abstract

摘要： 目的：探讨白细胞介素6（IL-6）与乳头状甲状腺癌（PTC）发病的关系，阐明IL-6在PTC发生发展中的作用及其可能机制。方法：收集5例PTC患者（病例1组）、5例桥本甲状腺炎（HT）并发PTC患者（病例2组）和5名查体正常人（正常组）的血清，采用酶联免疫吸附（ELISA）法检测各组研究对象血清中IL-6水平。收集20例PTC （PTC组）、15例HT并发PTC患者（HT+PTC组）病变甲状腺组织和18名正常人（对照组）甲状腺组织，采用免疫组织化学（IHC）法检测各组研究对象甲状腺组织中IL-6、IL-6受体（IL-6R）、核因子κB （NF-κB）和RET/PTC蛋白表达阳性率；分析IL-6、IL-6R与RET/PTC、NF-κB表达的关联性。结果：PTC患者甲状腺组织内上皮细胞复杂乳头状增生伴细胞核毛玻璃样，并见核沟及核内包涵体；HT并发PTC患者甲状腺组织中除了PTC典型病变外，还可以看见弥漫淋巴组织浸润伴淋巴滤泡形成，增生与萎缩甲状泡上皮共存伴甲状腺上皮嗜酸性变，间质纤维化；正常甲状腺组织小叶结构存在，滤泡细胞大小一致。ELISA法检测，PTC组和HT并发PTC组患者血清IL-6水平高于正常组（P<0.05）；IHC法检测，PTC组患者甲状腺组织中IL-6、IL-6R、NF-κB和RET/PTC表达阳性率高于对照组（P<0.05）。IL-6、IL-6R与NF-κB、RET/PTC蛋白表达有关联（P<0.05）。结论：IL-6可能通过RET/PTC-NF-κB信号通路参与PTC的发生发展。

关键词: 甲状腺肿瘤, 甲状腺乳头状癌, 白细胞介素6, 核因子κB, RET/PTC

Abstract: Objective:To investigate the relationship between interleukin-6 (IL-6) and papillary thyroid carcinoma (PTC), and to elucidate the role of IL-6 in the occurrence and development of PTC and its possible mechanism. Methods:The serum levels of IL-6 were measured by ELISA method in 5 patients with PTC(case 1 group), 5 patients with Hashimoto thyroiditis (HT) complicated with PTC(case 2 group) and 5 normal persons(normal group). The thyroid tissues of 20 patients with PTC(PTC group), 15 patients with HT complicated with PTC(HT +PTC group) and 18 normal persons(control group) were collected. The positive expression rates of IL-6, IL-6 receptor (IL-6R), nuclear factor kappa-B(NF-κB) and RET/PTC proteins in thyroid tissue of the subjects in various groups were detected by immunohistochemistry(IHC) method; the relationships between IL-6, IL-6R and NF-κB, RET/PTC expressions were analyzed. Results:In the patients with PTC, the complex papillary hyperplasia of thyroid epithelial cells accompanying with ground glass like nuclei and nuclear sulcus and inclusions were seen; in the patients with HT complicated with PTC, in addition to the typical pathological changes of PTC, the diffuse lymphoid tissue infiltration accompanying with lymphoid follicle formation,and the coexistence of hyperplasia and atrophic thyroid follicular epithelium with eosinophic degeneration of thyroid epithelium and interstitial fibrosis were also found. The lobular structrure of normal thyroid tissue was found,and the follicular cells were in the same size The ELISA results showed that the serum IL-6 levels of the patients in PTC group and HT+ PTC group were higher than those in normal group (P<0.05);the IHC results showed that the positive expression rates of IL-6, IL-6R, NF-κB, and RET/PTC in thyroid tissue of the patients in PTC group were higher than those in control group (P<0.05). The expressions of IL-6,and IL-6R were positively correlated with the expressions of NF-κB and RET/PTC protein (P<0.05). Conclusion:IL-6 may be involved in the occurrence and development of PTC through the RET/PTC-NF-B signal pathway.

Key words: papillary thyroid carcinoma, interleukin-6, nuclear factor kappa-B, RET/PTC

中图分类号:

R736.1

黑利娟, 王娟红, 魏威, 方航荣, 段瑛, 马士芬, 徐俊荣. 乳头状甲状腺癌患者血清和甲状腺组织中白细胞介素6水平的检测及其意义[J]. 吉林大学学报(医学版), 2019, 45(03): 601-605.

HEI Lijuan, WANG Juanhong, WEI Wei, FANG Hangrong, DUAN Ying, MA Shifen, XU Junrong. Detection of interleukin-6 levels in serum and thyroid tissue of patients with papillary thyroid carcinoma and their significances[J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 601-605.

参考文献

[1] RAHIB L, SMITH B D, AIZENBERG R, et al. Projecting cancer incidence and deaths to 2030:the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11):2913-2921.
[2] EROL V, MAKAY Ö, CÖZG, et al. The importance of staging systems for the determination of prognosis of well-differentiated thyroid cancer[J].Ulus Cerrahi Derg, 2013,29(1):7-10.
[3] NIX P, NICOLAIDES A, COATESWORTH A P. Thyroid cancer review 1:presentation and investigation of thyroid cancer[J]. Int J Clin Pract, 2005,59(11):1340-1344.
[4] VITA R, IENI A, TUCCARI G, et al. The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma[J].Rev Endocr Metab Disord, 2018,19(4):301-309.
[5] KNÜPFER H, PREISS R. Serum interleukin-6 levels in colorectal cancer patients-a summary of published results[J]. Int J Colorectal Dism, 2010, 25(2):135-140.
[6] 姜春霞, 陈阔. 胃癌患者血清中肿瘤坏死因子-α和白介素-6水平检测及其临床诊断价值[J]. 肿瘤基础与临床, 2017,30(1):74-75.
[7] SANTER F R, MALINOWSKA K, CULIG Z, et al. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells[J]. Endocr Relat Cancer, 2010, 17(1):241-253.
[8] YEH K Y, LI Y Y, HSIEH L L, et al. Analysis of the effect of serum interleukin-6(IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer[J]. Jpn J Clin Oncol, 2010, 40(6):580-587.
[9] PROVATOPOULOU X, GEORGIADOU D, SERGENTANIS T N, et al. Interleukins as markers of inflammation in malignant and benign thyroid disease[J].Inflamm Res, 2014, 63(8):667-674.
[10] CHUNG J H, LEE Y C, EUN Y G, et al. Single nucleotide polymorphism of interleukin-18 and interleukin-18 receptor and the risk of papillary thyroid cancer[J]. Exp Clin Endocrinol Diabetes, 2015,123(10):598-603.
[11] 杨毅, 张洁, 王智勇,等. SHP₂介导IL-6促进乳腺癌细胞侵袭作用机制的研究[J]. 中国肿瘤临床, 2016, 43(18):792-796.
[12] LUMACHI F, BASSO S M M, ORLANDO R. Cytokines, thyroid diseases and thyroid cancer[J]. Cytokine, 2010,50(3):229-233.
[13] HOLTE E, KLEVELAND O, UELAND T, et al. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction[J]. Heart, 2017,103(19):1521-1527.
[14] BARTON B E, MURPHY T F. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen[J]. Cytokine, 2001,16(6):251-257.
[15] TONG J, WANG Y, DA J P. Usefulness of CK₁₉, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions[J]. Zhonghua Zhong Liu Za Zhi, 2011,33(8):599-604.
[16] ZHOU DH, LI Z, BAI X F. BRAFV₆₀₀E and RET/PTC promote proliferation and migration of papillary thyroid carcinoma cells in vitro by regulating nuclear factor-κB[J]. Med Sci Monit, 2017,23:5321-5329.
[17] HONG L L, QIN J S, HUANG J X, et al. Expression and significance of NF-κB p65 and CyclinD1 in papillary thyroid carcinoma[J]. Hainan Med J, 2014,11(12):1853-1855.
[18] PRASAD S, RAVINDRAN J, AGGARWAL B B. NF-κB and cancer:how intimate is this relationship[J]. Mol Cell Biochem, 2010, 336(1/2):25-37.
[19] VISCONTI R, CERUTTI J, BATTISTA S, et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression[J]. Oncogene, 1997,15(16):1987-1994.
[20] FAGIN J A. How thyroid tumors start and why it matters:kinase mutants as targets for solid cancer pharmacotherapy[J]. J Endocrinol, 2004,183(2):249-256.
[21] RHODEN K J, UNGER K, SALVATORE G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes:follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma[J]. J Clin Endocrinol Metab, 2006,91(6):2414-2423.
[22] WIRTSCHAFTER A, SCHMIDT R, ROSEN D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis[J]. Laryngoscope, 1997,107(1):95-100.

乳头状甲状腺癌患者血清和甲状腺组织中白细胞介素6水平的检测及其意义

Detection of interleukin-6 levels in serum and thyroid tissue of patients with papillary thyroid carcinoma and their significances

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	姚红月, 刘新宇, 刘婉珠. 人参二醇组皂苷对四氯化碳所致大鼠急性肝损伤的保护作用及其机制[J]. 吉林大学学报(医学版), 2019, 45(03): 479-483.
[2]	郭佳, 宋思奇, 王克宇. 热射病小鼠大脑皮层组织中炎症细胞因子水平及P38MAPK/P65NF-κB信号通路变化[J]. 吉林大学学报(医学版), 2019, 45(03): 566-571.
[3]	何琦, 史华, 丹阳, 邵素菊. 加味丹参饮对慢性心力衰竭大鼠心脏功能和血清炎性因子IL-6及TNF-α的影响[J]. 吉林大学学报(医学版), 2019, 45(01): 63-68.
[4]	赵菁, 刘剑, 张敏, 吴珊, 赵本正, 陈俊宇, 金延泽. 除草剂阿特拉津的免疫毒性及其对大鼠免疫功能的影响[J]. 吉林大学学报(医学版), 2018, 44(06): 1163-1168.
[5]	魏佳, 王瑶琪, 孙旭, 逄仁柱, 杨帅, 石亮, 李勇, 孟宪瑛. 甲状腺癌相关基因及其在临床诊断中应用的研究进展[J]. 吉林大学学报(医学版), 2018, 44(04): 880-885.
[6]	王海彬, 董志军, 郭立涛, 石晶, 董微丽. 菩人丹超微粉对STZ诱导糖尿病大鼠视网膜病变的保护作用及其对NF-κB信号通路的影响[J]. 吉林大学学报(医学版), 2018, 44(04): 759-763.
[7]	郑燕, 王娜, 吴命坤, 刘静乔, 孟亚丽. 米非司酮对稽留流产患者血清和绒毛组织中Ang-1、Ang-2、VEGF、TNF-α和IL-6表达水平的影响[J]. 吉林大学学报(医学版), 2018, 44(04): 791-795.
[8]	行敏, 任宏伟, 屈慧明, 耿龙. 寻常型银屑病患者血清中IL-17的表达及紫草素对IL-17刺激HaCaT细胞分泌IL-6和IL-23的影响[J]. 吉林大学学报(医学版), 2017, 43(05): 958-962.
[9]	赵朋, 付彤, 张秀祥, 战越, 关欣, 石爱平. 乳腺癌伴甲状腺癌和皮肌炎1例报告及3种疾病关联性文献复习[J]. 吉林大学学报(医学版), 2017, 43(05): 1015-1018.
[10]	杨竹君, 侯旭, 于文雯, 闫阔, 申玉芹, 孙新华. MT01对实验性牙移动大鼠牙周组织中TLR9、TRAF6和IL-6表达水平的影响[J]. 吉林大学学报(医学版), 2017, 43(04): 752-756.
[11]	刘瑞东, 付彤, 韩冰, 董丙飞, 孟伟, 宋东. 侧方异位甲状腺1例报告及文献复习[J]. 吉林大学学报(医学版), 2017, 43(03): 640-642.
[12]	陆国秀, 张国旭, 郝珊瑚, 郭佳, 张文文, 张景华, 王治国. 不同体质量指数阿尔茨海默病患者PET/CT联合显像和IL-6水平及ApoE表达率检测及其临床意义[J]. 吉林大学学报(医学版), 2017, 43(03): 611-614.
[13]	赵治艳, 盛今东, 刘宝国. 恶性甲状腺肿物和甲状腺乳头状癌Ⅵ区淋巴结转移的危险因素[J]. 吉林大学学报(医学版), 2017, 43(02): 334-338.
[14]	徐烁, 孟宪瑛, 逄仁柱, 杨帅, 韩佳滨, 孙旭, 朱继红. Ki-67和BRAF基因突变与甲状腺乳头状癌侵袭性关系的研究进展[J]. 吉林大学学报(医学版), 2016, 42(06): 1259-1262.
[15]	温剑平, 崔永生, 张雄基. 转染EGFRL858R的肺腺癌细胞中IL-6和VEGF表达水平及其意义[J]. 吉林大学学报(医学版), 2016, 42(03): 502-505.